The benefit of measurement of B-type natriuretic peptide for monitoring the treatment of chronic cardiac failure
Authors:
I. Málek; M. Kubánek
Published in the journal:
Kardiol Rev Int Med 2007, 9(3): 154-158
Summary
Chronic heart failure is connected with the activation of sympatoadrenal and other humoral systems. Activation of vasoconstrictive/proliferative systems is to some extent counterbalanced by natriuretic peptides and other vasoactive substances. The evaluation of natriuretic peptides, especially BNP is valuable in the diagnosis of heart failure, assessment of actual hemodynamic status, development of symptoms and prognosis. However, there is not enough evidence that knowledge of BNP dynamics directly influence therapeutic decisions. In patients after heart transplantation increased blood concentration of BNP is not a consequence of acute rejection, but can be hold as a marker of subclinical graft damage, which could influence the fate of the patient.
Keywords:
B-natriuretic peptide – heart failure – cardiac transplantation
Zdroje
1. Mc Cullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Circulation 2002; 106: 416–422.
2. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982.
3. Lupínek P, Málek I, Kubánek M et al. N-terminální proBNP u nemocných s pokročilým srdečním selháním: význam pro neinvazivní odhad hemodynamického stavu. Cor Vasa 2005; 47: 371–374.
4. Schou M, Gustafsson F, Nielsen PH et al. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Failure 2007; 9: 68–74.
5. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292–299.
6. Gardner RS, Olzap F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735–1743.
7. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397.
8. O’Brien R, Squire IB, Demme B et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5: 499–506.
9. Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641.
10. Málek I. Transplantace srdce. Pohled kardiologa. Praha: Triton 2004: 31–36.
11. Kubánek M, Málek I, Kautzner J et al. The value of B-type natriuretic peptide and big endothelin-1 for detection of severe pulmonary hypertension in heart transplant candidates. Eur J Heart Failure 2005; 7: 1149–1155.
12. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–1233.
13. Annand IS, Fisher LD, Chiang Y et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality
and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278–1283.
14. Frantz RP, Olson LJ, Grill D et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005; 149: 541–547.
15. Hartmann F, Packer M, Coats AJS et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004; 6: 343–50.
16. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 5: 2454–2458.
17. Troughton RW, Frampton ChM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–1130.
18. Lainchbury JG, Troughton W, Frampton ChM et al. NT-pro BNP-guided drug treatment for chronic heart failure:
design and methods in the “BATTLESCARRED” trial. Eur J Heart Fail 2006; 8: 532–538.
19. Kubánek M, Málek I, Bytešník J et al. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 2006; 8: 832–840.
20. Hammerer-Lercher A, Mair J, Antretter H et al. B-type natriuretic peptide as a marker of allograft rejection after heart transplantation. J Heart Lung Transplant 2005; 24: 1444.
21. Cuppoletti A, Roig E, Perez-Villa F et al. Value of NT-proBNP determinations in the follow-up of heart transplantation.
Transplant Proc 2005; 37: 4033–4035.
22. Bedáňová H, Petrikovits E, Nečas J et al. NT-proBNP jako neinvazivní marker akutní rejekce u pacientů po transplantaci srdce. Cor Vasa 2006; 48: 388–390.
23. Kňazeje M, Málek I, Kment M, Pirk J. Stanovení NT-pro BNP jako neinvazivního markeru rejekce po transplantaci srdce. Cor Vasa 2004; 4(Suppl): 40.
24. Wu AH, Johnson ML, Aaronson KD et al. Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant 2005; 24: 52–57.
25. Mehra MR, Uber PA, Potluri S et al. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004; 94: 454–458.
26. Ambrosi P, Oddoze C, Riberi A et al. Usefulness of N-terminal-pro-brain natriuretic peptide levels in predicting survival in heart transplant recipients. Am J Cardiol 2004; 94: 1585–1587.
27. Špinar J, Hradec J, Meluzín J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007; 49(Suppl K): 5–34.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2007 Číslo 3
Najčítanejšie v tomto čísle
- Monitoring peroral anticoagulation therapy in outpatient practice
- Importance of implantable loop recorder in patients with unexplaided syncope
- CURRENT MEDICAL LITERATURE LTD, LONDON 1998, 438S.
- Pulmonary arterial hypertension